LY3938577 phase 1 study (healthy adults and type 2 diabetes)
What this study tests
Lilly’s first-in-human LY3938577 study enrolled 66 healthy adults or adults with type 2 diabetes. It completed in June 2024, with no results posted. It contains no T1D participants and does not establish glucose-responsive action in humans.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2024-07-24.
Most recent recorded citation date: 2023-11-17. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults 18-70. Healthy participants and participants with type 2 diabetes. No type 1 diabetes participants. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- The registry records 66 actual participants, study completion on June 28, 2024 and no posted results as of September 16, 2026. Later trials show continued development, not proof that this study established safety or efficacy.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Part A: number of participants with one or more adverse events and serious adverse events
- Part B: number of participants with one or more adverse events and serious adverse events
- Part A: incidence of hypoglycemia from baseline to day 16
The full picture
Population and evidence boundary
This Phase 1 study tested LY3938577 in healthy adults and adults with type 2 diabetes. Adverse events and hypoglycemia were registered outcomes. No results are posted in the study record.
Later registration of T1D and T2D studies does not establish the result of this trial. It is included as development context; it is not T1D efficacy evidence. Earlier wording calling it the first human test of the current glucose-responsive-insulin generation and inferring safety from corporate progression has been removed.
Sources
- [1]A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes · Trial registry · 2023-11-17 — Phase 1, n=66, started 17 Nov 2023, completed 28 Jun 2024. Healthy adults and type 2 diabetes only. Incidence of hypoglycemia is a primary endpoint. No results posted as of Aug 2026.